Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Cross Country Healthcare is a national leader in providing innovative healthcare w...
Cross Country Healthcare is a national leader i...
At Electromedical Technologies, we believe results speak louder than words. Since ...
At Electromedical Technologies, we believe resu...
We have specialized in dermatology, as your skin's health is our concern. We aim t...
We have specialized in dermatology, as your ski...
We are a network of full-service medical equipment companies that use tailored pro...
We are a network of full-service medical equipm...
BrainsWay is an industry leader in the field of transcranial magnetic stimulation ...
BrainsWay is an industry leader in the field of...
Hypertension Diagnostics designs, develops, manufactures, and markets proprietary...
Hypertension Diagnostics designs, develops, ma...
Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission...
Teligent is a specialty generic pharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.